Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVABAY PHARMACEUTICALS, INC.

(NBY)
  Report
Delayed Nyse  -  04:00 2022-09-23 pm EDT
0.1100 USD   -8.86%
09/23NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
BU
09/22NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
BU
09/13NOVABAY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Beauty Stocks Benefit from Surge in Spending (HBRM, NBY, NOVN, RGS, COTY)

08/10/2022 | 06:23am EDT

During the pandemic, skincare companies saw a small downtick in growth which can be attributed to fewer people going outside, and thereby a decreased emphasis on exterior beauty. After all, the photo filters on phones do a great job of removing blemishes. However, with fewer masks and more face-to-face contact consumers are pouring money back into beauty.

The overall beauty market was up to $511B in 2021 from $483B in 2020 - and with an annual compounded growth rate of 4.75% worldwide - it's predicted to exceed $716B by 2025. And $784.6B by 2027.

*Cosmetics is projected to grow from $90b to $118b (+32%)

*Skincare is projected to grow from $136b to $169b (+24.3%)

*Personal care is projected to grow from $226b to $268b (+18.7%)

*Fragrances is projected to grow from $53b to $60b (+13.7%)

SKINCARE FINANCIALS COMING THIS WEEK AND BEYOND

Investors are now ready to see how this growth has manifested in securities over the last quarter.

One sub-industry in skincare with a busy few weeks of reporting ahead is acne treatment. The global acne treatment market is projected to grow from $9.36 billion in 2022 to $12.97 billion by 2029, exhibiting a CAGR of 4.8% in forecast period (Forbes Business Insights). According to the National Center for Biotechnology Information (NCBI), the prevalence of acne affected 9.4% of the global population in 2021.

Herborium Group, Inc. (OTCMKTS: HBRM) CEO Dr. Agnes Olszewski noted in a recent interview ahead of her company's 3rd quarter financials, "We see an uptick in 3rd quarter sales generally, and with the launch of our new platform this could be accelerated." The company's revenues have increased steadily over the past 4 years. This quarter, HBRM plans to launch its AI-powered diagnosis platform for e-commerce. Herborium offers Botanical Therapeutic ® remedies for acne the company tests its natural formulations with the same standards found in the pharmaceutical industry creating higher efficacy, proven safety, and consumer satisfaction.

HBRM's AI solution for e-commerce is particularly intriguing considering the online share of the skincare market is predicted to surge to 48% in the United States by 2023. Learn more about HBRM here: https://topnewsguide.com/2022/08/04/herborium-group-otcmkts-hbrm-financials-trend-up-signaling-major-catalysts/

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) with its two brands, Avenova® and DERMAdoctor® is set to announce second quarter results this week. NBY will report financial results for the three and six months ended June 30, 2022, after market close on Thursday, August 11, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Thursday will be a busy day for skincare financial reporting as Novan, Inc. (Nasdaq: NOVN), will report its second quarter 2022 financial results as well. NOVN is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Novan recently completed the acquisition of EPI Health and its robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams.

CLOUD-BASED TECH CHANGING THE BEAUTY INDUSTRY

We've noted that over the past six months, HBRM has accelerated its transformation from an Acne Treatment Company to become an interactive, AI-based platform for integrated product, content and expertise in the area or skincare. Regis Corporation (NYSE: RGS), a leader in the haircare industry, announced today the completion of the sale of Opensalon® Pro (OSP) to Zenoti, the leading technology provider for beauty, wellness, and fitness businesses. Zenoti will become the sole salon technology platform for all of Regis' brands. With this relationship, Zenoti will help Regis deliver a modern, digital experience to drive engagement with its three million salon customers every month. Regis salons will begin transitioning to the Zenoti platform as early as July. Zenoti powers more than 20,000 beauty, wellness and fitness business in more than 50 countries with its comprehensive, cloud-based, mobile-led solution elevates the guest experience, unifies the brand, and streamlines operations.

Another beauty company shifting to digital delivery, Coty Inc. (NYSE: COTY), one of the world's leading beauty companies and global leaders in fragrance, announced a "Global Travel Retail Joint Business Partnership" with Ant Group to enhance the cooperation in digitalization. The agreement will support digital platforms like Alipay and other digital payment methods at a global level through Alipay+, a suite of global cross-border mobile payments and marketing solutions operated by Ant Group.

Investors looking for "beautiful" returns should look to these beauty stocks. Start your research on HBRM here: https://topnewsguide.com/2022/08/04/herborium-group-otcmkts-hbrm-financials-trend-up-signaling-major-catalysts/

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport 'CGR' is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR is compensated one thousand eight hundred dollars monthly via wire transfer by Herborium Group to produce and syndicate content related to HBRM. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

Media Contact

Company Name: Capital Gains Report

Contact Person: Mark McKelvie

Email: mark@capitalgainsreport.com

City: NAPLES

State: FLORIDA

Country: United States

Website: https://capitalgainsreport.com/

Source: www.abnewswire.com

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
COTY INC. -7.05% 7.38 Delayed Quote.-29.71%
HERBORIUM GROUP, INC. 0.00% 0.0002 Delayed Quote.-50.00%
NOVABAY PHARMACEUTICALS, INC. -8.86% 0.11 Delayed Quote.-67.95%
NOVAN, INC. -4.35% 1.76 Delayed Quote.-57.79%
REGIS CORPORATION 4.40% 0.98 Delayed Quote.-43.68%
All news about NOVABAY PHARMACEUTICALS, INC.
09/23NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
BU
09/22NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
BU
09/13NOVABAY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered S..
AQ
09/13NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum
BU
09/12NovaBay Pharmaceuticals Enters Into Agreements for a Private Placement and Warrant Repr..
AQ
09/12NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Showcase DERMAdoctor'..
BU
09/09NovaBay Pharmaceuticals Expects to Receive Up to $5.3 Million From Private Placement, R..
MT
09/09NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Repr..
BU
09/09NovaBay Pharmaceuticals, Inc. announced that it expects to receive $3.25 million in fun..
CI
08/11TRANSCRIPT : NovaBay Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
More news
Analyst Recommendations on NOVABAY PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 14,9 M - -
Net income 2022 -4,75 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,22x
Yield 2022 -
Capitalization 7,15 M 7,15 M -
Capi. / Sales 2022 0,48x
Capi. / Sales 2023 0,30x
Nbr of Employees 30
Free-Float 80,2%
Chart NOVABAY PHARMACEUTICALS, INC.
Duration : Period :
NovaBay Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVABAY PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,11 $
Average target price 2,80 $
Spread / Average Target 2 445%
EPS Revisions
Managers and Directors
Justin M. Hall President, CEO, Director & General Counsel
Andrew Jones Chief Financial Officer & Treasurer
Paul E. Freiman Chairman
Yen You Zheng Independent Director
Swan Sit Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NOVABAY PHARMACEUTICALS, INC.-67.95%7
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.18.40%24 099